Mezzion Secures $20 Million to Advance Phase 3 Trial of Udenafil for Rare Congenital Heart Disease
Key Insights
Mezzion Pharma secured approximately $20 million in strategic funding led by Midas-Meritz New Technology Finance Association (search) to support the ongoing global Phase 3 FUEL-2 trial of udenafil for Fontan circulation (search) patients.
The investment represents strong institutional confidence in Mezzion's late-stage pipeline, with lead investor Midas PE citing positive FUEL-1 results and expressing belief in udenafil's potential for successful Phase 3 completion and regulatory approval.
The financing follows growing clinical momentum, including the introduction of dedicated ICD-10 codes for Fontan-associated conditions, marking progress in addressing this long-overlooked rare congenital heart disease (search) population.
Mezzion Pharma Co., Ltd. announced a major milestone in their clinical development program, having secured approximately $20 million USD in strategic funding to support the ongoing global Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation (search). The financing was led by Midas-Meritz New Technology Finance Association (search) and KDBC-Korea Investment & Securities New Technology Investment Association (search), representing a strong vote of confidence from top-tier institutional investors in Mezzion's late-stage pipeline and long-term growth strategy.
Strategic Investment in Rare Disease Innovation
The lead investor, Midas PE, is a prominent private equity firm with over $230 million in assets under management. CEO Lim Chun-soo expressed strong confidence in Mezzion's clinical program, stating: "After a detailed review of Mezzion's FUEL-1 results and the ongoing FUEL-2 protocol, we believe udenafil is well positioned for successful global Phase 3 completion and regulatory approval. We are proud to support Mezzion as it expands internationally and continues its leadership in rare disease innovation."
Dean Park, Chairman and CEO of Mezzion, emphasized the significance of this partnership: "We are pleased to partner with Midas Private Equity (search) (Midas PE) and KDBC as we enter a critical phase in the development of udenafil for the Fontan population, a community with significant unmet medical need. This investment affirms the strength of our data, the quality of our science, and the potential impact of our work on patients worldwide."
Growing Clinical and Regulatory Momentum
This financing follows growing clinical and regulatory momentum for Mezzion. The introduction of dedicated ICD-10 codes for Fontan-associated conditions marks a major step forward in recognizing and addressing the needs of this long-overlooked population. It enhances care, improves coverage, and underscores Mezzion's leadership and long-term commitment to advancing treatment for rare congenital heart disease (search).
Chairman Park noted positive trial progress, adding: "With accelerating enrollment and growing engagement across clinical sites, we believe time and data are now working in our favor. We have initially secured $20 million, and we will continue our efforts to receive valuable investments in the future."
About Udenafil and Fontan Circulation
Udenafil represents a first-in-class therapy for patients with Fontan physiology (search), a rare congenital heart condition. The drug is currently being evaluated in global Phase 3 trials, building on the foundation of positive FUEL-1 results that have attracted investor confidence.
Mezzion Pharma Co., Ltd., based in South Korea and listed on the KOSDAQ (140410), develops treatments for rare and underserved diseases. Its U.S. subsidiary, Mezzion Pharmaceuticals, Inc. (search), headquartered in New Jersey, leads global clinical development and commercialization efforts for the company's pipeline of innovative therapies targeting unmet medical needs in rare disease populations.